Diagnostic and Prognostic Values of NSCLC Patients with or Without Obstructive Pneumonia After Sleeve Lobectomy

Overview

Journal Front Cell Infect Microbiol

Specialties Cell Biology
Infectious Diseases
Microbiology

Date 2024 Dec 30

PMID 39735257

Authors

Yuxia Huang

Lan Zhang

Wentian Zhang

Na Lv

Tao Wang

Affiliations

Soon will be listed here.

Abstract

Objective: We aimed to identify the diagnostic value of next-generation sequencing (NGS) of bronchoalveolar lavage fluid (BALF) from patients with non-small-cell lung cancer (NSCLC).

Methods: Forty patients who were initially diagnosed with pulmonary nodules were enrolled. Frozen section histology was used to identify the NSCLC cell types. NGS of collected BALF samples was used for microbial identification. We compared the bacterial and viral distributions in BALF samples from patients with NSCLC with and without obstructive pneumonia as well as their NSCLC drainage times following surgery.

Results: Of the 29 patients with NSCLC, eight had obstructive pneumonia. , , and were the top three bacteria present in almost 50% of patients, both with and without obstructive pneumonia. The viral detection rate was higher in the BALF of patients with NSCLC who did not have obstructive pneumonia. However, in patients with NSCLC and drain times of >5 days, the human herpes virus type 7 detection rate was higher following surgery than it was in patients with NSCLC who had drain times of ≤5 days.

Conclusion: Viral imbalance in NSCLC is closely related to the occurrence of obstructive pneumonia and postoperative drainage time.

References

Wang X, Guo Y, Liu L, Wei J, Zhang J, Xie T . YAP1 protein expression has variant prognostic significance in small cell lung cancer (SCLC) stratified by histological subtypes. Lung Cancer. 2021; 160:166-174. DOI: 10.1016/j.lungcan.2021.06.026. View

Ramirez-Labrada A, Isla D, Artal A, Arias M, Rezusta A, Pardo J . The Influence of Lung Microbiota on Lung Carcinogenesis, Immunity, and Immunotherapy. Trends Cancer. 2020; 6(2):86-97. DOI: 10.1016/j.trecan.2019.12.007. View

Alswat A . The Influence of the Gut Microbiota on Host Health: A Focus on the Gut-Lung Axis and Therapeutic Approaches. Life (Basel). 2024; 14(10). PMC: 11509314. DOI: 10.3390/life14101279. View

Morelli T, Fujita K, Redelman-Sidi G, Elkington P . Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy. Thorax. 2021; 77(3):304-311. PMC: 8867274. DOI: 10.1136/thoraxjnl-2021-217260. View

Rizzo A, Cusmai A, Giovannelli F, Acquafredda S, Rinaldi L, Misino A . Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. Cancers (Basel). 2022; 14(6). PMC: 8945985. DOI: 10.3390/cancers14061404. View

Santoni M, Rizzo A, Kucharz J, Mollica V, Rosellini M, Marchetti A . Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunol Immunother. 2023; 72(6):1365-1379. PMC: 10992808. DOI: 10.1007/s00262-022-03349-4. View

Sheweita S, Alsamghan A . Molecular Mechanisms Contributing Bacterial Infections to the Incidence of Various Types of Cancer. Mediators Inflamm. 2020; 2020:4070419. PMC: 7366195. DOI: 10.1155/2020/4070419. View

Liu K, Zhang W, Tan Q, Jiang G, Jia J . Antibiotic use is a negative predictor of the efficacy and toxicity of epidermal growth factor receptor-targeted therapy in advanced non-small cell lung cancer. Oncol Lett. 2019; 18(3):2677-2683. PMC: 6676747. DOI: 10.3892/ol.2019.10481. View

Zheng L, Sun R, Zhu Y, Li Z, She X, Jian X . Lung microbiome alterations in NSCLC patients. Sci Rep. 2021; 11(1):11736. PMC: 8175694. DOI: 10.1038/s41598-021-91195-2. View

10.

Goto T . Airway Microbiota as a Modulator of Lung Cancer. Int J Mol Sci. 2020; 21(9). PMC: 7246469. DOI: 10.3390/ijms21093044. View

11.

Budisan L, Zanoaga O, Braicu C, Pirlog R, Covaliu B, Esanu V . Links between Infections, Lung Cancer, and the Immune System. Int J Mol Sci. 2021; 22(17). PMC: 8431665. DOI: 10.3390/ijms22179394. View

12.

Beck J, Young V, Huffnagle G . The microbiome of the lung. Transl Res. 2012; 160(4):258-66. PMC: 3440512. DOI: 10.1016/j.trsl.2012.02.005. View

13.

Nichols L, Saunders R, Knollmann F . Causes of death of patients with lung cancer. Arch Pathol Lab Med. 2012; 136(12):1552-7. DOI: 10.5858/arpa.2011-0521-OA. View

14.

Sok M, Dragas A, Erzen J, Jerman J . Sources of pathogens causing pleuropulmonary infections after lung cancer resection. Eur J Cardiothorac Surg. 2002; 22(1):23-7; discussion 27-9. DOI: 10.1016/s1010-7940(02)00244-0. View

15.

Jiang L, Huang J, Jiang S, Rong W, Shen Y, Li C . The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer. Cancer Immunol Immunother. 2021; 70(8):2313-2321. PMC: 7844548. DOI: 10.1007/s00262-021-02847-1. View

16.

Ma H, Dong Z, Zhang X, Liu C, Liu Z, Zhou X . Airway bacterial microbiome signatures correlate with occupational pneumoconiosis progression. Ecotoxicol Environ Saf. 2024; 284:116875. DOI: 10.1016/j.ecoenv.2024.116875. View

17.

Yu D, Liu Z . The research progress in the interaction between and cancers. Front Microbiol. 2022; 13:988734. PMC: 9554461. DOI: 10.3389/fmicb.2022.988734. View

18.

Wong-Rolle A, Wei H, Zhao C, Jin C . Unexpected guests in the tumor microenvironment: microbiome in cancer. Protein Cell. 2020; 12(5):426-435. PMC: 8106554. DOI: 10.1007/s13238-020-00813-8. View

19.

Mao Q, Jiang F, Yin R, Wang J, Xia W, Dong G . Interplay between the lung microbiome and lung cancer. Cancer Lett. 2017; 415:40-48. DOI: 10.1016/j.canlet.2017.11.036. View

20.

Rizzo A . Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate. Br J Cancer. 2022; 127(8):1381-1382. PMC: 9553978. DOI: 10.1038/s41416-022-01929-w. View